

Platinum(II) and Ruthenium(II) Coordination complexes equipped with an anchoring site for binding the protein kinase enzyme pockets: synthesis, molecular docking and biological assays.

Matthieu Scarpi-Luttenauer,¹ Katia Galentino,² Christophe Orvain^{3,4}, Audrey Fluck,¹ Marco Cecchini,² Georg Mellitzer^{3,4}, Christian Gaiddon,^{3,5,*} Pierre Mobian^{*1}

¹ Université de Strasbourg, CNRS, UMR 7140, F-67000 Strasbourg, France

² Université de Strasbourg, CNRS, UMR 7177, F-67000 Strasbourg, France

³ Inserm U1113 IRFAC, Team STREINTH, Strasbourg, France

⁴ present address: INSERM, UMR 1260, CRBS, Regenerative Nanomedicine, “GP_SMIT” Laboratory, CRBS; 1 Rue Eugène Boeckel, 67085 Strasbourg, France

⁵ present address: UMR7242, Biotechnology et Signalisation Cellulaire, group STREINTH, 300 Bld S. Brant, FR-67412 Illkirch Cedex, France

Figure S1. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(1)**

Figure S2. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Ru(1)**

Figure S3. ESI-MS spectrum + simulated spectrum and close-up of **Ru(1)**

Figure S4. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(2)**

Figure S5. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Ru(2)**

Figure S6. ESI-MS spectrum + simulated spectrum and close-up of **Ru(2)**

Figure S7. ¹H NMR spectrum (CDCl₃, 500 MHz) of **Ru(3)**

Figure S8. ¹³C NMR spectrum (CDCl₃, 126 MHz) of **Ru(3)**

Figure S9. ESI-MS spectrum + simulated spectrum and close-up of **Ru(3)**

Figure S10. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(4)**

Figure S11. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Ru(4)**

Figure S12. ESI-MS spectrum + simulated spectrum and close-up of **Ru(4)**

Figure S13. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(5)**

Figure S14. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Ru(5)**

Figure S15. ESI-MS spectrum + simulated spectrum and close-up of **Ru(5)**

Figure S16. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Pt(1)**

Figure S17. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Pt(1)**

Figure S18. HR-MS spectrum + simulated spectrum and close-up of **Pt(1)**

Figure S19. ¹H NMR spectrum (D₂O, 500 MHz) of **Pt(2)**

Figure S20. ^{13}C NMR spectrum (D_2O , 126 MHz) of **Pt(2)**

Figure S21. HR-MS spectrum + simulated spectrum and close-up of **Pt(2)**

Figure S22. ^1H NMR spectrum (MeOD , 500 MHz) of **Pt(3)**

Figure S23. ^{13}C NMR spectrum (MeOD , 126 MHz) of **Pt(3)**

Figure S24. HR-MS spectrum + simulated spectrum and close-up of **Pt(3)**

Figure S25. ^1H NMR spectrum (CD_3CN , 500 MHz) of **Pt(4)**

Figure S26. ^{13}C NMR spectrum (CD_3CN , 126 MHz) of **Pt(4)**

Figure S27. HR-MS spectrum + simulated spectrum and close-up of **Pt(4)**

Figure S28. Hydrolysis kinetics of **Ru(1-5)**

Figure S29. Hydrolysis kinetics of **Pt(1-4)**

Figure S30. HPLC-MS analysis of **Ru(3)**

Figure S31. Re-docking of known MST2 and S6K1 inhibitors

Figure S32. Ellipsoid plot of the **Ru(2)** crystal structure.

Figure S33. Ellipsoid plot of the **Pt(4)** crystal structure.

Figure S34. Western Blots

Table S1. Analysis of the interaction pattern of the ruthenium and platinum compounds at S6K1 as predicted by docking

Table S2. Analysis of the interaction pattern of the ruthenium and platinum compounds at MST2

Antibodies list

^1H , ^{13}C NMR spectra and ESI-MS spectra of the synthesized complexes




Figure S1. ^1H NMR spectrum (CD_3CN , 500 MHz) of **Ru(1)**




Figure S2. ^{13}C NMR spectrum (CD_3CN , 126 MHz) of Ru(1)




Figure S3. ESI-MS spectrum + simulated spectrum and close-up of Ru(1)




Figure S4. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(2)**




Figure S5. ¹³C NMR spectrum (CD₃CN, 126 MHz) of **Ru(2)**




Figure S6. ESI-MS spectrum + simulated spectrum and close-up of **Ru(2)**




Figure S7. ¹H NMR spectrum (CDCl₃, 500 MHz) of **Ru(3)**




Figure S8. ¹³C NMR spectrum (CDCl₃, 126 MHz) of Ru(3)




Figure S9. ESI-MS spectrum + simulated spectrum and close-up of Ru(3)




Figure S10. ¹H NMR spectrum (CD₃CN, 500 MHz) of Ru(4)




Figure S11. ¹³C NMR spectrum (CD₃CN, 126 MHz) of Ru(4)




Figure S12. ESI-MS spectrum + simulated spectrum and close-up of **Ru(4)**




Figure S13. ¹H NMR spectrum (CD₃CN, 500 MHz) of **Ru(5)**




Figure S14. ¹³C NMR spectrum (CD₃CN, 126 MHz) of Ru(5)




Figure S15. ESI-MS spectrum + simulated spectrum and close-up of **Ru(5)**




Figure S16. 1H NMR spectrum (D_2O , 500 MHz) of **Pt(1)**




Figure S17. ^{13}C NMR spectrum (D_2O , 126 MHz) of **Pt(1)**




Figure S18. ESI-MS spectrum + simulated spectrum and close-up of **Pt(1)**




Figure S19. 1H NMR spectrum (CD₃CN, 500 MHz) of **Pt(2)**




Figure S20. ^{13}C NMR spectrum (CD₃CN, 126 MHz) of Pt(2)




Figure S21. HR-MS spectrum + simulated spectrum and close-up of Pt(2)




Figure S22. ¹H NMR spectrum (MeOD, 500 MHz) of Pt(3)




Figure S23. ¹³C NMR spectrum (MeOD, 126 MHz) of Pt(3)




Figure S24. HR-MS spectrum + simulated spectrum and close-up of **Pt(3)**




Figure S25. 1H NMR spectrum (CD₃CN, 500 MHz) of **Pt(4)**




Figure S26. ^{13}C NMR spectrum (CD₃CN, 126 MHz) of **Pt(4)**




Figure S27. HR-MS spectrum + simulated spectrum and close-up of **Pt(4)**




Figure S28: Hydrolysis kinetics of **Ru(1-5)** measured by UV-Vis absorption in a PBS buffer for 24 h (one spectrum every hour). A slight drop in intensity was observed for the analyzed complexes, which was explained by the medium evaporation. a) **Ru(1)**, b) **Ru(2)**, c) **Ru(3)**, d) **Ru(4)**, e) **Ru(5)**.




Figure S29: Hydrolysis kinetics of **Pt(1-4)** measured by UV-Vis absorption in a PBS buffer for 24 h (one spectrum every hour). A slight drop in intensity was observed for the analyzed complexes, which was explained by the medium evaporation. a) **Pt(1)**, b) **Pt(2)**, c) **Pt(3)**, d) **Pt(4)**.

THR135, LEU13 and VAL21) as the reference in the crystal structure. Panel B. re-docking of 5BS in MST2 (PDB code: 5dh3.pdb). In blue is depicted the co-crystallized ligand and in magenta the re-docked molecule. In green are highlighted the hydrophobic interactions and in yellow the hydrogen bonds. The docking score of this binding mode is -76.72. In this binding pose 5BS establishes both the same H-bonds (with CYS102, LYS298 and ASP109) and hydrophobic interactions (with LEU33 and TYR101) as the reference in the crystal structure.




Figure S32: Ellipsoid plot of the Ru(2) crystal structure.






Figure S33: Ellipsoid plot of the Pt(4) crystal structure.


pS6 p-S235/236




pS6 p-S235/236 2



pS6 p-S235/236 3



pYAP p-S127



pYAP p-S127 2


Lane	Condition	Concentration
1	DNA Ladder	-
2	Ctrl	2 μ M
3	Ru(3)	2 μ M
4	Ru(3)	25 μ M
5	Ru(5)	2 μ M
6	Ru(5)	25 μ M
7	Pt(3)	2 μ M
8	Pt(3)	25 μ M
9	Pt(4)	2 μ M
10	Pt(4)	25 μ M
11	Empty	-

pYAP p-S127 3


Ctrl Ru(3) Ru(5) Pt(3) Pt(4)

2 μ M 25 μ M 2 μ M 25 μ M 2 μ M 25 μ M 2 μ M 25 μ M


S6




S6 2




S6 3




YAP




YAP 2




YAP 3




Actin from S6



Actin from S6 2



Actin from S6 3






Figure S34: Western Blots

Residue (PDB:	Residue (this paper)	Interaction type	Pt(3)	Pt(4)	Ru(3)	Ru(5)
------------------	-------------------------	---------------------	-------	-------	-------	-------

4RLP)						
E173/O	GLU-73	H bond	-	-	-	-
L175/N	LEU-75	H bond	✓	-	-	-
K99/O	LYS-99	H bond	-	-	-	-
Y174/OH	TYR74	H bond	-	✓	-	-
L97	LEU-13	VdW	✓	✓	-	-
V105	VAL-21	VdW	✓	-	✓	✓
A121	ALA-37	VdW	✓	✓	-	✓
T235	THR-135	VdW	✓	-	✓	✓

Table S1. Analysis of the interaction pattern of the ruthenium and platinum compounds at S6K1 as predicted by docking relative to the reference compounds FL772 solved in complex with the protein (PDB:4RLP). The interactions were analyzed using the software PLIP.⁴² Green checks highlight when the interaction was detected in the lowest-energy binding mode by docking.

Residue (PDB: 5DH3)	Residue (this paper)	Interaction type	Pt(3)	Pt(4)	Ru(3)	Ru(5)
C102/O	CYS-102	H bond	✓	✓	-	-
C102/N	CYS-102	H bond	✓	-	-	-
D109/OD1	ASP-109	H bond	✓	-	-	-
L33	LEU-33	VdW	✓	✓	-	✓
V41	VAL-41	VdW	-	-	-	✓
Y101	TYR-101	VdW	-	-	-	✓

L153	LEU-153	VdW	✓	-	✓	✓
------	---------	-----	---	---	---	---

Table S2. Analysis of the interaction pattern of the ruthenium and platinum compounds at MST2 as predicted by docking relative to the reference compounds XMU-MP-1 solved in complex with the protein (PDB:5DH3). The interactions were analyzed using the software PLIP.⁴² Green checks highlight when the interaction was detected in the lowest-energy binding mode by docking.

Antibodies List

β-Actin (anti-mouse) from Merck Millipore, anti-mouse (7076), anti-rabbit (7074), pS235/236-S6 Ribosomal Protein (anti-rabbit, D57.2.2E), S6 Ribosomal Protein (anti-rabbit, 5G10) and pS127-YAP (anti-rabbit, S127-D9W2I) from Cell Signaling technology and YAP (anti-mouse, sc-101190) from Santa Cruz Biotechnology and all antibodies were used at 1:1000 dilutions except for pS6 (1:2000), actin (1:15000), anti-mouse (1:2000), and anti-rabbit (1:10000).